➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 5,004,613

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,004,613
Title: Oral sustained release pharmaceutical formulation and process
Abstract:A pharmaceutical sustained release tablet or tablet layer is formed by making a wet granulation, using povidone (PVP) in water or alcohol-water as the granulating fluid which is mixed with a pharmaceutical active, hydroxyethyl cellulose, a wicking agent e.g. microcrystalline cellulose, then drying and milling the granulation and blending with dry powdered erosion promotor, e.g. pregelantinized starch, additional wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a slow release of the pharmaceutical active.
Inventor(s): Radebaugh; Galen W. (Chester, NJ), Murtha; John L. (Holland, PA), Glinecke; Robert (Glenside, PA)
Assignee: McNeil-PPC, Inc. (Milltown, NJ)
Application Number:07/392,748
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,004,613
Patent Claim Types:
see list of patent claims
Dosage form; Process; Composition; Formulation;

Drugs Protected by US Patent 5,004,613

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,004,613

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001288   Start Trial
Australia 611704   Start Trial
Canada 1315202   Start Trial
Germany 3880762   Start Trial
European Patent Office 0305051   Start Trial
Spain 2054813   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.